Carl Zeiss Meditec (OTCMKTS:CZMWY – Get Free Report) was downgraded by stock analysts at Barclays from a “hold” rating to a “strong sell” rating in a report released on Wednesday, Zacks reports.
A number of other equities analysts have also commented on the company. UBS Group lowered Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 11th. Morgan Stanley started coverage on Carl Zeiss Meditec in a research report on Wednesday, September 2nd. They set an “underweight” rating for the company. Zacks Research raised Carl Zeiss Meditec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Finally, The Goldman Sachs Group lowered Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a report on Monday, October 5th. Two equities research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Carl Zeiss Meditec currently has a consensus rating of “Strong Sell”.
Read Our Latest Stock Analysis on Carl Zeiss Meditec
Carl Zeiss Meditec Trading Down 0.8%
Shares of CZMWY stock opened at $35.14 on Wednesday. The stock has a 50 day simple moving average of $36.75 and a 200 day simple moving average of $33.01. Carl Zeiss Meditec has a 1 year low of $26.65 and a 1 year high of $53.40.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG is a medical technology company headquartered in Jena, Germany, and part of the ZEISS Group. The company develops, manufactures and distributes equipment and solutions for ophthalmology and microsurgery, serving hospitals, clinics and medical professionals worldwide. Its ophthalmic portfolio includes diagnostic systems for examining the eye, equipment for cataract and refractive surgery, surgical lasers, intraocular lenses and other related products. The company also supplies surgical microscopes, visualization systems and digital technologies used in neurosurgery, spine surgery, ear, nose and throat procedures, and other microsurgical specialties.
See Also
- Five stocks we like better than Carl Zeiss Meditec
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.
